Cofrogliptin

Warnings and Precautions

Overall: in the two phase 3 trials, side effects were mostly mild and passed without treatment or stopping the medicine. The most common was a rise in the enzyme lipase on blood tests (4.5% on 10 mg vs 1.9% on placebo), followed by raised amylase (1.3% vs 0.6%), abnormal liver tests (1.9% vs 1.3%), urinary tract infection (1.3% vs 0.6%) and high uric acid (1.0% vs 0%).

• Pancreatitis: no cases were seen in the trials, but other medicines of this class have been linked to acute pancreatitis. Stop the tablets and contact your doctor if you get severe, lasting stomach pain, sometimes spreading to the back.
• Heart failure: some medicines in this class were linked to heart failure in large studies. People with a history of heart failure or kidney problems should discuss this first and report breathlessness, swelling of the ankles or sudden weight gain.
• Liver: a liver test is advised before starting. Report tiredness, loss of appetite, pain in the upper right tummy, dark urine or yellow eyes.
• Low blood sugar: rare in the trials (3.8% on 10 mg alone vs 1.9% on placebo; 4.5% with metformin) and never severe. There are no data with sulfonylureas or insulin, which could raise the risk.
• Allergy and skin: serious allergic reactions, swelling of the face or throat, blistering skin (bullous pemphigoid) and severe joint pain have been reported with other DPP-4 inhibitors. Seek help if any of these appear.
• Kidneys: a fall in kidney filtration (eGFR below 60) was seen in 1.6% on 10 mg vs 1.3% on placebo.

Who should not take it: anyone allergic to cofrogliptin or any ingredient of the tablet. It is not recommended in pregnancy or breastfeeding, and its safety in people under 18 has not been established. Long-term heart safety studies have not yet been done.

How to Access Cofrogliptin in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation & Availability

What documents are required to import Cofrogliptin to India?

The tablets can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:

• A valid prescription from a qualified diabetologist, endocrinologist or physician
• Recent reports confirming type 2 diabetes, such as HbA1c and fasting glucose, plus a kidney and liver function test
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

Once we have received and checked a valid prescription and, where needed, an import permit.

Is Cofrogliptin available in India?

No. It is approved only in China. It does not appear in CDSCO's lists of new drugs approved in India, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.

Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. Because it is taken only twice a month, a few boxes cover several months of treatment.

It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.

Sourcing & Delivery

NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. Each box holds one blister of four 5 mg tablets, which is two doses, or four weeks of treatment at the usual 10 mg every two weeks. The tablets are kept sealed, protected from light and below 25°C, so they travel in their original packs under temperature-controlled shipping. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.

For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.

Availability Across Major Cities in India

Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating clinic on a valid doctor's prescription.

Delhi

Diabetes clinics in Delhi see patients from across North India, and being close to our New Delhi dispatch point keeps delivery times short.

Mumbai

Diabetologists in Mumbai can request the medicine for a named patient, and several months of supply can be planned in one order.

Bangalore

Patients in Bangalore can have the tablets delivered home or to their clinic once the prescription has been checked.

Chennai

A major centre for diabetes care in South India, where the treating doctor can send the prescription and HbA1c report to start the import.

Hyderabad

Endocrinologists in Hyderabad can coordinate access for patients who would find a two-weekly tablet easier to stick to.

Kolkata

For Kolkata and the eastern states, deliveries are timed so the next two-weekly dose is never missed.

Pune

Patients in Pune can use the same documented import route, with updates shared at each stage.

Ahmedabad

Gujarat has a large number of people living with type 2 diabetes, and doctors here can request supply for individual patients.

Jaipur

Patients in Jaipur and across Rajasthan can receive the tablets at home or at the treating clinic.

Chandigarh

Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the patient or the clinic.

Lucknow

We arrange delivery to patients and diabetes clinics across Uttar Pradesh.

Kochi

Kerala has one of the highest diabetes rates in India, and patients here can receive the medicine in Kochi and nearby cities.

Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.